GM. Yongqiang Chen
Bachelor of Physics, Senior Engineer. After successfully founded a medical software company, he becoming a leading player in its niche market. He founded Wuxi FreshAir in 2006 and dephina in Germany in 2013. He has long focused on R&D, management, and business operations for safety and energy conservation in life science environments.
He has led the development of projects such as plasma system, FPAQS pathological air quality control system, ClabAir medical laboratorysystem and thermal comfort system for buildings. He has obtained numerous Chinese and German invention patents, including for specialized air treatment technology, high-efficiency radiant air conditioning systems, and sensor control technology for diagnostic and treatment environments.
He has led the development of projects such as plasma system, FPAQS pathological air quality control system, ClabAir medical laboratorysystem and thermal comfort system for buildings. He has obtained numerous Chinese and German invention patents, including for specialized air treatment technology, high-efficiency radiant air conditioning systems, and sensor control technology for diagnostic and treatment environments.
CTO. Hua Qian
PhD in Mechanical Engineering from the University of Hong Kong. He has led and overseen key R&D projects, including the Phelan RICU aerodynamic infection control system, the animal laboratory airflow quantitative exposure test system, and the evidence-based research on the dynamic mechanisms of radiant air conditioning and the human respiratory tract.
He has published over 200 papers, 136 of which have been indexed by the SCI, with over 9,000 citations in SCI journals and six highly cited papers (top 1%) in the ESI rankings. Two of his papers are recommended by the US Environmental Protection Agency as key documents on "Indoor Air and COVID-19" (2/54). His papers have been cited six times in WHO standards and over ten times in official policy documents from countries including the US, UK, and Germany.
He has published over 200 papers, 136 of which have been indexed by the SCI, with over 9,000 citations in SCI journals and six highly cited papers (top 1%) in the ESI rankings. Two of his papers are recommended by the US Environmental Protection Agency as key documents on "Indoor Air and COVID-19" (2/54). His papers have been cited six times in WHO standards and over ten times in official policy documents from countries including the US, UK, and Germany.
